Adaptive Clinical Trials

Lead Research Organisation: University of Cambridge

Abstract

Classically designing a clinical trial involves making assumptions about various attributes, such as the treatment effect, before any data are collected. The aim of our programme is to introduce novel designs that are more flexible. The rigidity of the classic design can lead to failed studies due to wrong assumptions such as using an optimistic treatment effect to limit the size of the study. Our novel designs will allow the use of accrued information in many ways; this includes stopping the study early for futility or efficacy, re-assessing the size of the study and recruiting more patients if need be altering dose choices during the study and identifying subgroups of patients who respond the best to treatment. Our overall goal is to minimise the number of people needed within a study whilst maintaining the statistical rigour needed to correctly answer the scientific questions.

Technical Summary

Clinical trials are considered the gold-standard study design when testing for a causal effect of a new treatment or intervention. There are, however, many challenges to be faced in the future. The high, and increasing, cost of clinical trials has caused the drug development process to become more and more expensive (DiMasi, Grabowski, and Hansen 2016), meaning new design and analysis methods to increase efficiency are greatly needed. The barriers to using adaptive clinical trials are lifting, which is leading to an increasing uptake (Hatfield et al. 2016). Members of my team are working on several current and future trials that are implementing novel methods. This portfolio of trials forms a strong basis for our future methodology research plans. I have the capacity, skills and track-record to push the methodology forward to tackle even more ambitious problems. These include dealing with patient heterogeneity, exploiting multivariate outcomes in dose-finding/ranging trials, using historical data, applying bandit methodology to improve patient benefit in trials, and conducting trials within large cohorts.

I have been successful in building links with industry with several ongoing collaborations and two postdoctoral positions jointly funded by GlaxoSmithKline (GSK) and AstraZeneca (AZ).

My proposed future work includes five main objectives:
1. proposing novel trial design and analysis approaches for patient stratification to predict treatment benefit;
2. developing multi-arm multi-stage methodology that can be applied to a broader range of trial designs and types of endpoint;
3. extending and further enhancing model-free and model-robust methodology for dose- finding and ranging trial designs;
4. improving the efficiency of trials within small populations;
5. using the richness of complex outcomes to give more informative inference.

Publications

10 25 50

publication icon
Wason J (2017) A multi-stage drop-the-losers design for multi-arm clinical trials. in Statistical methods in medical research

publication icon
Bowden J (2017) Unbiased estimation for response adaptive clinical trials. in Statistical methods in medical research

publication icon
Kunz CU (2017) Two-stage phase II oncology designs using short-term endpoints for early stopping. in Statistical methods in medical research

publication icon
Bond S (2019) Theory of general balance applied to step wedge designs. in Statistics in medicine

publication icon
Bowden J (2016) Weighing Evidence "Steampunk" Style via the Meta-Analyser. in The American statistician

publication icon
Willemsen RH (2018) Frequent Monitoring of C-Peptide Levels in Newly Diagnosed Type 1 Subjects Using Dried Blood Spots Collected at Home. in The Journal of clinical endocrinology and metabolism

publication icon
Grayling M (2018) Group Sequential Clinical Trial Designs for Normally Distributed Outcome Variables in The Stata Journal: Promoting communications on statistics and Stata

publication icon
Grayling M (2018) Calculations Involving the Multivariate Normal and Multivariate t Distributions with and without Truncation in The Stata Journal: Promoting communications on statistics and Stata

 
Description AIM-HY
Amount £43,679 (GBP)
Organisation Medical Research Council (MRC) 
Sector Public
Country United Kingdom
Start 01/2015 
End 12/2019
 
Description EPAD-
Amount € 654,000 (EUR)
Funding ID 115736 
Organisation European Commission 
Department Innovative Medicines Initiative (IMI)
Sector Public
Country Belgium
Start 04/2015 
End 03/2020
 
Description HTMR Network Award
Amount £3,071 (GBP)
Funding ID N97 
Organisation Medical Research Council (MRC) 
Sector Public
Country United Kingdom
Start 01/2018 
End 09/2018
 
Description INNODIA
Amount € 500,000 (EUR)
Funding ID 115797 
Organisation European Commission 
Department Innovative Medicines Initiative (IMI)
Sector Public
Country Belgium
Start 10/2015 
End 09/2022
 
Description MBU grant
Amount £17,059 (GBP)
Organisation University of Edinburgh 
Department MRC DPFS Resoure Centre
Sector Academic/University
Country United Kingdom
Start 11/2014 
End 02/2017
 
Description NIHR HTA (Epilepsy Nurse)
Amount £52,826 (GBP)
Organisation National Institute for Health Research 
Sector Public
Country United Kingdom
Start 04/2013 
End 11/2015
 
Description NIHR XP grant
Amount £10,597 (GBP)
Organisation National Institute for Health Research 
Sector Public
Country United Kingdom
Start 09/2015 
End 03/2020
 
Description NIHR- Jonathan Mant
Amount £85,434 (GBP)
Organisation National Institute for Health Research 
Sector Public
Country United Kingdom
Start 04/2015 
End 03/2020
 
Description AZ - Jodrell phase I 
Organisation AstraZeneca
Country United Kingdom 
Sector Private 
PI Contribution We have only just initiated this collaboration so we have been shortlisting and trying to recruit
Collaborator Contribution Shortlisting and recruiting
Impact A trial called ATRIUM is being developed currently
Start Year 2014
 
Description AZ - Jodrell phase I 
Organisation Cancer Research UK Cambridge Institute
Country United Kingdom 
Sector Academic/University 
PI Contribution We have only just initiated this collaboration so we have been shortlisting and trying to recruit
Collaborator Contribution Shortlisting and recruiting
Impact A trial called ATRIUM is being developed currently
Start Year 2014
 
Description AZ joint postdoc 
Organisation AstraZeneca
Country United Kingdom 
Sector Private 
PI Contribution We have a joint position to look at Phase I dose escalation designs
Collaborator Contribution Provide advice and scientific directin.
Impact None yet.
Start Year 2017
 
Description CTU joint positin 
Organisation Cambridge University Hospitals NHS Foundation Trust
Department Cambridge Clinical Trials Unit
Country United Kingdom 
Sector Hospitals 
PI Contribution We have a joint position to work on dual agent dose escalation studies.
Collaborator Contribution Scientific input
Impact None yet
Start Year 2017
 
Description Diabetes Research 
Organisation University of Cambridge
Department Cambridge Institute for Medical Research (CIMR)
Country United Kingdom 
Sector Academic/University 
PI Contribution Involved in multiple trials involving Il-2 dose/frequency finding
Collaborator Contribution They ran the trial and gave the scientific steer
Impact Publications and talks all completed/delivered
Start Year 2011
 
Description Maxine's PhD 
Organisation GlaxoSmithKline (GSK)
Country Global 
Sector Private 
PI Contribution I am the academic supervisor of this CASE award, the industry partners are within GSK. I give the main methodology direction of the project
Collaborator Contribution Partners give scientific and practical guidance into the project
Impact Several workshops delivered to GSK and AZ
Start Year 2013
 
Description Polypill 
Organisation University of Cambridge
Department Cambridge Institute of Public Health
Country United Kingdom 
Sector Academic/University 
PI Contribution Co-applicant on program grant, developing trial design with research team.
Collaborator Contribution Scientific direction and running trial
Impact Unfortunately this grant terminated as the trial was too difficult to implement in the time alloted
Start Year 2011
 
Description Roche phase I trial design 
Organisation Roche Pharmaceuticals
Country Global 
Sector Private 
PI Contribution We have engaged with industry to try and implement methods in practice. We have had some meetings and some presentations but also we have some joint work ongoing to help implement the PIPE design methodology
Collaborator Contribution The partners have listened and are committed to trying methods out in practice. Currently one of the their phase I trial designs is using the dual-agent design PIPE in one of their early phase trials (ClinicalTrials.gov Identifier: NCT02760797).
Impact Two trials were implemented and the results are in Roche.
Start Year 2014
 
Description WRAP study 
Organisation Medical Research Council (MRC)
Department MRC Human Nutrition Research Group
Country United Kingdom 
Sector Academic/University 
PI Contribution Trial design expertise and how to handle missing data
Collaborator Contribution Scientific direction and running the trial
Impact Paper accepted and work complete
Start Year 2012
 
Title GROUPSEQ: Stata module providing functions to determine group sequential trial designs 
Description A selection of functions to determine the boundaries and sample size required by several common group sequential designs, for two-arm trials with continuous outcome variables. 
Type Of Technology Software 
Year Produced 2017 
Impact Several trial statisticians and methodologists have subsequently been in contact to ask for further information around the design of group sequential clinical trials, particularly in Stata. 
URL https://ideas.repec.org/c/boc/bocode/s458345.html
 
Title MVTNORM: Stata module to work with the multivariate normal and multivariate t distributions 
Description A set of commands that allow users to compute the distribution function, density, equi-coordinate quantiles, and random vectors of the multivariate normal and multivariate t distributions. Any non-degenerate cases of the multivariate normal and multivariate t distributions can be worked with, along with a particular class of non-central multivariate t distributions. The commands are written in a combination of Stata and Mata for speed. 
Type Of Technology Software 
Year Produced 2017 
Impact MVTNORM has subsequently allowed the creation of the GROUPSEQ module for designing group sequential clinical trials. 
URL https://ideas.repec.org/c/boc/bocode/s458043.html
 
Description Adaptive Designs Talk at PSI conference 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Professional Practitioners
Results and Impact This talk raised the awareness of the Hub Network activities in adaptive trial designs. There was some discussion of the methods and discussion about being available for consultative purposes.

No notable impacts
Year(s) Of Engagement Activity 2013
 
Description Adaptive Designs symposium at the Institute of Psychiatry 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach Regional
Primary Audience Professional Practitioners
Results and Impact There was some interesting debates about adaptive designs

Raised our visibility in Psychiatry
Year(s) Of Engagement Activity 2013
 
Description Adaptive designs training course at Pavia University, Italy 
Form Of Engagement Activity Participation in an activity, workshop or similar
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Professional Practitioners
Results and Impact We gave a 3 day training course on adaptive trial designs with practicals in R.
Year(s) Of Engagement Activity 2017
 
Description Armitage Lectures 
Form Of Engagement Activity Participation in an activity, workshop or similar
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Professional Practitioners
Results and Impact Annual workshop and lecture created and hosted by the MRC Biostatistics Unit, to honour the immense contributions of Professor Peter Armitage who was at the unit from 1947 to 1961, and whose work is recognised throughout the world as achieving a successful balance between methodological rigour and applied commonsense, to which all statisticians aspire. An eminent medical statistician visits for a week and works with members of the unit. The highlight is the Armitage Lecture, where more than 100 delegates attend. This event raises the unit research profile and creates new collaborations.
Year(s) Of Engagement Activity 2012,2013,2014,2015,2016,2017
URL https://www.mrc-bsu.cam.ac.uk/news-and-events/armitage-lectureships-and-workshops/
 
Description BSU Open Day 
Form Of Engagement Activity Participation in an open day or visit at my research institution
Part Of Official Scheme? No
Geographic Reach Local
Primary Audience Schools
Results and Impact Unit held open day as part of MRC Festival of Medical Research.

The aim of the open day was to welcome secondary school students and members of the general public to come to the unit, find out about the research the unit does, and to take part in activities that illustrate BSU research, with the overall theme being 'Fun with statistics'. An open day of this format was a first for the unit and overall it was a very successful event. There were 40 attendees over a 4 hour event. All attendees pre-booked and were split into 4 groups for a 1 hour session comprising of an introduction, participation in hands-on activities, and a brief careers talk. The small groups and length of session allowed for quality engagement between the scientists and the audience.

Feedback from the attendees was very positive, and the wider MRC Festival activities that took place in Cambridge demonstrated the benefits in delivering these types of events.
Year(s) Of Engagement Activity 2016
URL http://www.mrc-bsu.cam.ac.uk/bsu-open-day-2016-why-are-statistics-important/
 
Description Big Biology Day 2018 
Form Of Engagement Activity Participation in an activity, workshop or similar
Part Of Official Scheme? No
Geographic Reach Regional
Primary Audience Public/other audiences
Results and Impact Presented 2x outreach activities for general public audiences (adults and children) on basic statistical methods that represent the research carried out by the BSU. Audiences enjoyed and engaged with activities, and altered views on the importance of statistics. Basic evaluation method carried out shows positive response from audience.
Year(s) Of Engagement Activity 2018
 
Description Cambridge Science Festival 
Form Of Engagement Activity Participation in an activity, workshop or similar
Part Of Official Scheme? No
Geographic Reach Regional
Primary Audience Public/other audiences
Results and Impact Each year BSU participate in Cambridge Science Festival - members of the general public explore and discuss issues of scientific interest and concern, through a series of different events. The festival also aims to raise aspirations by encouraging young people to consider a career in science, technology, engineering or mathematics.

BSU take part over two full days - 'Science Saturday' and the 'Cambridge Biomedical Campus' day. The unit presents a stand with 4 - 5 interactive activities that each communicate a basic statistical method or idea, representing one of the four research themes in the unit. Each year a new activity is developed and delivered requiring scientific input from staff and students across the unit. Over the two days, BSU engage with approximately 500 adults and children who visit the festival.
Year(s) Of Engagement Activity 2012,2013,2014,2015,2016,2017
URL http://www.sciencefestival.cam.ac.uk/
 
Description Cambridge Science Festival 2019 
Form Of Engagement Activity Participation in an activity, workshop or similar
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Public/other audiences
Results and Impact Stand at Cambridge Science Festival 2019, presenting two interactive hands-on activities developed by researchers across the BSU; one explaining probability and risk, and the other on precision medicine. Reaching out to 500+ audience members over 1 day.
Year(s) Of Engagement Activity 2019
 
Description Contributed talks at the 18th INFORMS Applied Probability Conference 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Professional Practitioners
Results and Impact SV gave contributed talks at the 18th INFORMS Applied Probability Conference and the 7th Greek Stochastics meeting. Talk entitled "Novel bandit-based solutions for practical stochastic scheduling problems".
Year(s) Of Engagement Activity 2015
URL http://www.stochastics.gr/meetings/eta/
 
Description Dose finding talk (Charleston) 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Professional Practitioners
Results and Impact Talk sparked a discussion on various dose-ranging aspects

No immediate impacts
Year(s) Of Engagement Activity 2014
 
Description Dose ranging talk (Cambridge) invited by the Cambridge Discussion Group 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach Regional
Primary Audience Professional Practitioners
Results and Impact Talk sparked a debate about these methods.

Made some industry links within Roche and Astra Zeneca
Year(s) Of Engagement Activity 2014
 
Description I'm a Scientist, Stay at Home 
Form Of Engagement Activity Engagement focused website, blog or social media channel
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Schools
Results and Impact PhD student Martin Law took part in online chat room activity, I'm a Scientist, Stay at Home, chatting with secondary school students about maths and statistics and answering their questions.
Year(s) Of Engagement Activity 2020
URL https://www.mrc-bsu.cam.ac.uk/blog/a-window-into-the-world-of-a-statistician/
 
Description Invited presentation at an early phase clinical conference (Paris) 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Professional Practitioners
Results and Impact I presented a novel clinical trial design on dual-agent dose escalation, there was a lot of interest from academics and industry. Since then I have worked closely with a member of Roche pharmaceuticals on how to implement these methods in practice.
Year(s) Of Engagement Activity 2015
 
Description Invited talk at CLDAG 2017 conference 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Professional Practitioners
Results and Impact I was an invited speaker to this international statistical conference. I spoke about adaptive dose ranging trial designs.
Year(s) Of Engagement Activity 2017
 
Description Invited talk at the PSI meeting on Extrapolation 
Form Of Engagement Activity Participation in an activity, workshop or similar
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Professional Practitioners
Results and Impact I was invited to give a talk on using historical data in trial inference and design.
Year(s) Of Engagement Activity 2017
 
Description Invited talk for the Breathlessness conference (Cambridge) 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Professional Practitioners
Results and Impact Adrian Mander gave a presentation on the various ways to adapt clinical trials to the area of palliative and end of life care. There has been numerous discussions since the talk by email with plans to produce a paper introducing this area to the wider audience undertaking these challenging trials.
Year(s) Of Engagement Activity 2015
 
Description Invited talk on early phase clinical trial designs (London) 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Professional Practitioners
Results and Impact 80 members of clinical trials units attended a workshop run by the NCRI, the talk on early phase designs was aimed at changing practice and how we design phase I trials.
Year(s) Of Engagement Activity 2015
 
Description Invited to give a departmental seminar on adaptive designs (Norwich) 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach Regional
Primary Audience Policymakers/politicians
Results and Impact Around 30 members of the clinical trials unit attended my talk on adaptive clinical trials, there was a great deal of interest and promises of future collaboration as there was a recognition that these methods will be needed in the near future
Year(s) Of Engagement Activity 2015
 
Description NCRI talk on phase I trials (Liverpool) 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Professional Practitioners
Results and Impact There was some debate and discussion.

None so far but this was the start of raising the awareness of better trials in oncology
Year(s) Of Engagement Activity 2012
 
Description Nuffield Placement Scheme 
Form Of Engagement Activity Participation in an open day or visit at my research institution
Part Of Official Scheme? No
Geographic Reach Regional
Primary Audience Other audiences
Results and Impact Statistician, Michael Grayling, took part in the Nuffiled Placement Scheme - supervising two A-Level students on a four week work experience placement at the Unit, both working on separate data analysis projects. Placements provided valuable experience for the students and helped them to understand the importance of statistics in clinical medicine. Both students have continued studying for A-Levels in maths and science subjects and plan to apply to study at University.
Year(s) Of Engagement Activity 2017
URL http://www.nuffieldfoundation.org/nuffield-research-placements
 
Description Nuffield Placement Scheme 2018 
Form Of Engagement Activity Participation in an open day or visit at my research institution
Part Of Official Scheme? No
Geographic Reach Regional
Primary Audience Schools
Results and Impact 3x students (aged 16-17, from regional schools) currently studying A-Levels took part in four week work experience placement at the Unit with aim of inspiring next generation of scientists. Each student was supervised by a different post-doc researcher (Mary Fortune. Michael Grayling and Kirsty Rhodes) and each took on a different statistical based project which contributed to BSU research. Students produced research poster and report at end of placement which will contribute to University applications and further career development. Valuable supervising and engagement experience for BSU post-doc researchers.
Year(s) Of Engagement Activity 2018
 
Description Oral presentation at the 23rd London Stata Users Group Meeting 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Professional Practitioners
Results and Impact Presented a talk entitled "Group sequential clinical trial designs for normally distributed outcome variables".
Year(s) Of Engagement Activity 2017
URL http://www.timberlake.co.uk/2017-stata-user-group-abstracts
 
Description Oral presentation at the Adaptive Designs and Multiple Testing Procedures Workshop 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Professional Practitioners
Results and Impact Presented a talk entitled "A two-stage Fisher exact-test for multi-arm trials with binary endpoints".
Year(s) Of Engagement Activity 2017
URL https://www.mrc-bsu.cam.ac.uk/event/adaptive-designs-multiple-testing-procedures-workshop-2017/
 
Description Oral presentation at the CEN-ISBS 2017 Joint Conference on Biometrics and Biopharmaceutical Statistics 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Professional Practitioners
Results and Impact Presented a talk, in a contributed session, entitled "Do single-arm trials have a role in drug development plans incorporating randomised trials?".
Year(s) Of Engagement Activity 2017
URL http://cenisbs2017.org/
 
Description Phase I course in dose-escalation adaptive designs at UCL 
Form Of Engagement Activity Participation in an activity, workshop or similar
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Professional Practitioners
Results and Impact This was a two day training course aimed at statisticians in early phase designs. There were also regulators at this meeting.
Year(s) Of Engagement Activity 2017
 
Description Poster presentation at the 38th Annual Conference of the International Society of Clinical Biostatistics 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Professional Practitioners
Results and Impact Presented a poster entitled "Admissible multi-arm stepped-wedge cluster randomized trial designs".
Year(s) Of Engagement Activity 2017
URL http://iscb2017.info/
 
Description Poster presentation at the 4th International Clinical Trials Methodology Conference (ICTMC) and the 38th Annual Meeting of the Society for Clinical Trials 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Professional Practitioners
Results and Impact Presented a poster entitled "Blinded and unblinded sample size re-estimation procedures for stepped wedge cluster randomised trials".
Year(s) Of Engagement Activity 2017
 
Description Poster presentation at the Current Developments in Cluster Randomised Trials and Stepped Wedge Design workshop 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Professional Practitioners
Results and Impact Presented a poster entitled "Design of an adaptive cluster randomised crossover trial, with application to the STRIVE trial".
Year(s) Of Engagement Activity 2017
 
Description Research Design Service (LONDON) 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach Regional
Primary Audience Professional Practitioners
Results and Impact I was invited to talk about adaptive clinical trials as part of a workshop of talks. There is a call for novel designs and my talk covered various methods that can be used to make trials more efficient
Year(s) Of Engagement Activity 2015
 
Description STEM Ambassador - Martin Law 
Form Of Engagement Activity Participation in an activity, workshop or similar
Part Of Official Scheme? No
Geographic Reach Regional
Primary Audience Schools
Results and Impact PhD Student, Martin Law, is a STEM Ambassador - participates in at least one STEM activity per year (statistics workshops for schools in 2017).
Year(s) Of Engagement Activity 2017
 
Description Statistical analysis for weight-loss trial (WRAP) 
Form Of Engagement Activity A broadcast e.g. TV/radio/film/podcast (other than news/press)
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Media (as a channel to the public)
Results and Impact Programme Leader Track, Adrian Mander, was co-author on peer-review publication in The Lancet on weight-loss trial (published April 2017). Paper received various local and national press attention, including article in The Guardian
Year(s) Of Engagement Activity 2017
URL https://www.theguardian.com/lifeandstyle/2017/may/04/give-overweight-patients-a-year-of-weight-loss-...
 
Description Talk about adaptive enrichment designs (Institute of Cancer Research 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach Regional
Primary Audience Professional Practitioners
Results and Impact We had a day long discussion about various potential collaborations

There were no massive impacts, a similar study was planned in their institute but it was too late to help improve it.
Year(s) Of Engagement Activity 2014
 
Description Talk at Clinical Trials in Small Populations workshop 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Professional Practitioners
Results and Impact SV was co-organiser of worksop, gave a tutorial on `Response-adaptive randomisation' during Day 1 and also contributed to one of the talks during Day 2 entitled 'Bringing patient population size into clinical trial design using response-adaptive randomisation'.
Year(s) Of Engagement Activity 2015
 
Description Talk at Lancaster University - Methodological work to make bandit models suitable to design (and improve) multi-armed clinical trial 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Professional Practitioners
Results and Impact SV invited speaker at workshop that gathered worldwide experts on ''bandit problems" (reinforcement learning bandits, restless bandits, non-parametric bandits, Bayesian bandits, etc., ) to discuss recent methodological advances and applications. SV spoke about recent methodological work to make bandit models suitable to design (and improve) multi-armed clinical trials.
Year(s) Of Engagement Activity 2016
 
Description Talk at the local RSS NW group 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach Regional
Primary Audience Professional Practitioners
Results and Impact A review talk on the multiple bandit-based designs publications of Sofia Villar
Year(s) Of Engagement Activity 2016
 
Description Talk on adaptive designs to Astra Zeneca 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Professional Practitioners
Results and Impact There was much interest in the methods and raised awareness of our group to the company

Since this talk we have secured a data sharing agreement and collaboration.
There are also 3 AZ post-docs that we have been linked with
Year(s) Of Engagement Activity 2013
 
Description Teaching at BAYES 2018: Bayesian Biostatistics Workshop 
Form Of Engagement Activity Participation in an activity, workshop or similar
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Professional Practitioners
Results and Impact Maxine Bennett was course leader at BAYES 2018: Bayesian Biostatistics on Bayesian approaches to incorporate historical data into clinical trials. Course attracted over 70 attendees from UK and internationally. Led to Maxine being asked to give same course at AstraZeneca.
Year(s) Of Engagement Activity 2018
 
Description Workshop provision at the Society for Social Medicine 61st Annual Scientific Meeting 
Form Of Engagement Activity Participation in an activity, workshop or similar
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Professional Practitioners
Results and Impact Assisted in the organisation and delivery of a workshop entitled "Novel trial designs and analytical methods for evaluating complex public health interventions: a discussion", in collaboration with members of the MRC Lifecourse Epidemiology Unit.
Year(s) Of Engagement Activity 2017